Hydroxychloroquine (HCQ) exhibits better binding to the main protease (Mpro) compared to spike protein (S protein) of SARS-CoV-2: An in-silico analysis

Deepa R. Bandi, SubbaRao V Tulimilli, Durai Ananda Kumar T., Chandi Kumari Chitturi, A. S. Bettadapura, Suma M. Natraj, S. Madhunapantula
{"title":"Hydroxychloroquine (HCQ) exhibits better binding to the main protease (Mpro) compared to spike protein (S protein) of SARS-CoV-2: An in-silico analysis","authors":"Deepa R. Bandi, SubbaRao V Tulimilli, Durai Ananda Kumar T., Chandi Kumari Chitturi, A. S. Bettadapura, Suma M. Natraj, S. Madhunapantula","doi":"10.2174/2212697x08666211210103711","DOIUrl":null,"url":null,"abstract":"\n\n Despite various efforts in preventing and treating SARS-CoV-2 infections; transmission and mortality have been increasing at alarming rates globally. Since its first occurrence in Wuhan, China, in December 2019, the number of cases and deaths due to SARS-CoV-2 infection continues to increase across 220 countries. Currently, there are about 228 million cases and 4.6 million deaths recorded globally. Although several vaccines/drugs have been reported to prevent or treat SARS-CoV-2, their efficacy to protect against emerging variants and duration of protection are not fully known. Hence, more emphasis is given to repurpose the existing pharmacological agents to manage the infected individuals. One such agent is hydroxychloroquine (HCQ), which is a more soluble derivative of antimalarial drug chloroquine. HCQ has been tested in clinical trials to mitigate SARS-CoV-2 infection-induced complications while reducing the time to clinical recovery (TTCR). However, several concerns and questions about the utility and efficacy of HCQ for treating SARS-CoV-2 infected individuals still persist. Identifying key proteins regulated by HCQ is likely to provide vital clues required to address these concerns.\n\n\n\n\nThe objective of this study is to identify the ability of HCQ for binding to the most widely studied molecular targets of SARS-CoV-2 viz., spike glycoprotein (S protein), and main protease (Mpro, also referred as chymotrypsin like protease) using molecular docking approaches and correlate the results with reported mechanisms of actions of HCQ.\n\n\n\n\nX-ray crystallographic structures of spike glycoprotein and main protease of SARS-CoV-2 were retrieved from Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). The structure of Hydroxychloroquine was retrieved from the PubChem compound database. The binding interactions of the HCQ with target proteins were predicted using C-Docker algorithm, and visualized using Discovery studio visualizer.\n\n\n\n\n Data from molecular docking studies showed very strong binding of HCQ to the main protease compared to spike glycoprotein.\n\n\n\n\nThe antiviral activity of HCQ is attributed to its ability to bind to the main protease compared to surface glycoprotein. Therefore, future studies should focus more on developing a combination agent/strategy for targeting surface glycoprotein and main protease together.\n\n","PeriodicalId":91228,"journal":{"name":"Clinical cancer drugs","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical cancer drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2212697x08666211210103711","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Despite various efforts in preventing and treating SARS-CoV-2 infections; transmission and mortality have been increasing at alarming rates globally. Since its first occurrence in Wuhan, China, in December 2019, the number of cases and deaths due to SARS-CoV-2 infection continues to increase across 220 countries. Currently, there are about 228 million cases and 4.6 million deaths recorded globally. Although several vaccines/drugs have been reported to prevent or treat SARS-CoV-2, their efficacy to protect against emerging variants and duration of protection are not fully known. Hence, more emphasis is given to repurpose the existing pharmacological agents to manage the infected individuals. One such agent is hydroxychloroquine (HCQ), which is a more soluble derivative of antimalarial drug chloroquine. HCQ has been tested in clinical trials to mitigate SARS-CoV-2 infection-induced complications while reducing the time to clinical recovery (TTCR). However, several concerns and questions about the utility and efficacy of HCQ for treating SARS-CoV-2 infected individuals still persist. Identifying key proteins regulated by HCQ is likely to provide vital clues required to address these concerns. The objective of this study is to identify the ability of HCQ for binding to the most widely studied molecular targets of SARS-CoV-2 viz., spike glycoprotein (S protein), and main protease (Mpro, also referred as chymotrypsin like protease) using molecular docking approaches and correlate the results with reported mechanisms of actions of HCQ. X-ray crystallographic structures of spike glycoprotein and main protease of SARS-CoV-2 were retrieved from Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). The structure of Hydroxychloroquine was retrieved from the PubChem compound database. The binding interactions of the HCQ with target proteins were predicted using C-Docker algorithm, and visualized using Discovery studio visualizer. Data from molecular docking studies showed very strong binding of HCQ to the main protease compared to spike glycoprotein. The antiviral activity of HCQ is attributed to its ability to bind to the main protease compared to surface glycoprotein. Therefore, future studies should focus more on developing a combination agent/strategy for targeting surface glycoprotein and main protease together.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
与严重急性呼吸系统综合征冠状病毒2型刺突蛋白(S蛋白)相比,羟氯喹(HCQ)与主要蛋白酶(Mpro)的结合更好:一项计算机分析
尽管在预防和治疗SARS-CoV-2感染方面做出了各种努力;全球传播和死亡率一直在以惊人的速度增长。自2019年12月在中国武汉首次出现SARS-CoV-2以来,220个国家因SARS-CoV-2感染而导致的病例和死亡人数继续增加。目前,全球约有2.28亿例病例和460万例死亡。虽然已有几种疫苗/药物报告可以预防或治疗SARS-CoV-2,但它们对新出现的变体的保护功效和保护时间尚不完全清楚。因此,更强调的是重新利用现有的药理学药物来管理受感染的个体。其中一种药物是羟氯喹(HCQ),它是抗疟药氯喹的一种更易溶的衍生物。HCQ已在临床试验中进行测试,以减轻SARS-CoV-2感染引起的并发症,同时缩短临床恢复时间(TTCR)。然而,关于HCQ治疗SARS-CoV-2感染者的效用和有效性的一些担忧和问题仍然存在。确定由HCQ调节的关键蛋白可能为解决这些问题提供重要线索。本研究的目的是利用分子对接方法确定HCQ与SARS-CoV-2最广泛研究的分子靶标即刺突糖蛋白(S蛋白)和主要蛋白酶(Mpro,也称为糜凝胰蛋白酶样蛋白酶)结合的能力,并将结果与已报道的HCQ的作用机制联系起来。从结构生物信息学研究合作实验室(RCSB)蛋白质数据库(PDB)中检索SARS-CoV-2的刺突糖蛋白和主要蛋白酶的x射线晶体结构。羟基氯喹的结构从PubChem化合物数据库中检索。使用C-Docker算法预测HCQ与目标蛋白的结合相互作用,并使用Discovery studio可视化工具进行可视化。分子对接研究的数据显示,与刺突糖蛋白相比,HCQ与主要蛋白酶的结合非常强。与表面糖蛋白相比,HCQ的抗病毒活性归因于其与主要蛋白酶的结合能力。因此,未来的研究应更多地着眼于开发表面糖蛋白与主要蛋白酶共同靶向的联合药物/策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Anti-Cancer Activity Evaluation of Naphthalenonic and Chromanonic Spiroisoxazoline Derivatives as Selective COX-2 Inhibitors on HT29 Cell Lines Current Perspective and Treatment Strategies in Targeted Therapy for Colorectal Cancer PAMAM Dendrimers: Revolutionizing the Targeted Cancer Therapy Neurotoxicity of Cisplatin as Monotherapy or Combined Chemotherapy in Cancer Treatment Hydroxychloroquine (HCQ) exhibits better binding to the main protease (Mpro) compared to spike protein (S protein) of SARS-CoV-2: An in-silico analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1